A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies

This study is testing a new CAR-T cell therapy called GF-CART01, which targets two proteins (CD19 and CD20) on cancer cells, in people with relapsed or treatment-resistant B-cell blood cancers — including diffuse large B-cell lymphoma and follicular lymphoma. **You may be eligible if...** - You are between 18 and 70 years old - You have confirmed B-cell lymphoma (DLBCL, follicular lymphoma, PMBCL, or high-grade B-cell lymphoma) whose cancer cells test positive for CD19 and/or CD20 - Your cancer has come back or not responded to at least two prior treatment regimens (including an anti-CD20 antibody and chemotherapy), or came back after a stem cell transplant - Your blood counts and organ function are adequate **You may NOT be eligible if...** - You have a different type of cancer at the same time (with limited exceptions) - Your heart, liver, or kidney function is significantly impaired - You received another experimental drug within the past 28 days Talk to your doctor to see if this trial is right for you.